SCHEMBL8534281

SCHEMBL8534281

CCCc1cc(C=C2SCNC2=O)cc(CCC)c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
NAT1 P18440 2/20 0.39
MEN1 O00255 2/20 0.37
POLB P06746 2/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
PTGS2 P35354 5/20 0.36
IGF1R P08069 3/20 0.36
PTGS1 P23219 3/20 0.36
CISD1 Q9NZ45 2/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
CTSD P07339 2/20 0.35
ALOX5 P09917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8534279 1.00 CYP1A2 (0.41) CYP1A2CYP3A4CYP2C9NAT1MEN1
SCHEMBL8535042 0.81 MEN1 (0.43) CYP1A2CYP3A4CYP2C9NAT1MEN1
SCHEMBL8535044 0.81 MEN1 (0.43) CYP1A2CYP3A4CYP2C9NAT1MEN1
SCHEMBL9684884 0.81 TNKS2 (0.39) CYP1A2CYP3A4CYP2C9NAT1MEN1
SCHEMBL9684891 0.81 TNKS2 (0.39) CYP1A2CYP3A4CYP2C9NAT1MEN1
SCHEMBL20005606 0.78 PIM1 (0.46) MEN1POLBKMT2ANPC1IGF1R
SCHEMBL3263474 0.75 PTGS2 (0.64) CYP1A2CYP2C9GAAPTGS2PTGS1
SCHEMBL3263476 0.75 PTGS2 (0.64) CYP1A2CYP2C9GAAPTGS2PTGS1
SCHEMBL8992017 0.75 PTGS2 (0.56) CYP1A2CYP3A4NAT1MEN1POLB
SCHEMBL8992013 0.75 PTGS2 (0.56) CYP1A2CYP3A4NAT1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0434394-B1 Compounds for treating inflammatory bowel disease LILLY CO ELI (US) 1998-08-05 EP disclosed
US-5731336-A USING ARYL-SUBSTITUTED RHODAMINES ELI LILLY AND COMPANY (US) 1998-03-24 US disclosed
US-5691367-A ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS ELI LILLY AND COMPANY (US) 1997-11-25 US disclosed
WO-1996022772-A1 METHOD FOR TREATING MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1996-08-01 WO disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
EP-0391644-B1 Aryl-substituted rhodanine derivatives LILLY CO ELI (US) 1996-06-19 EP disclosed
US-5387690-A Method of treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1995-02-07 US disclosed
US-5356917-A Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals ELI LILLY AND COMPANY (US) 1994-10-18 US disclosed
US-5216002-A Using benzyl substituted rhodanine derivatives as pure enantiomeric form ELI LILLY AND COMPANY (US) 1993-06-01 US disclosed
US-5158966-A Aryl-substituted rhodanine derivatives THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-10-27 US disclosed
EP-0500337-A1 Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-08-26 EP disclosed
EP-0434394-A2 Compounds for treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1991-06-26 EP disclosed
EP-0391644-A2 Aryl-substituted rhodanine derivatives ELI LILLY AND COMPANY (US) 1990-10-10 EP disclosed